check_circleStudy Completed
Rosacea
Bayer Identifier:
18575
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Preferences & Treatment Satisfaction Drivers in Rosacea Patients
Trial purpose
To survey patients with rosacea about their rosacea treatment preferences as well as to assess potential drivers of rosacea treatment satisfaction.
Key Participants Requirements
Sex
BothAge
18 - N/ATrial summary
Enrollment Goal
206Trial Dates
January 2015 - March 2016Phase
N/ACould I Receive a placebo
NoProducts
Finacea (Azelaic Acid, BAY39-6251)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Boston, United States |
Primary Outcome
- Self-reported concerns and importance of such concerns regarding their current topical rosacea treatmentsAssessed from the Rosacea Treatment Preference Questionnaire: Rated on a scale of 0 to 10, with 0 meaning not at all important and 10 meaning extremely importantdate_rangeTime Frame:Rosacea treatment in the past 4 weeksenhanced_encryptionNoSafety Issue:
Secondary Outcome
- Self-reported likelihood of switching to a topical rosacea treatmentsAssessed from the Rosacea Treatment Preference Questionnaire: Rated on a scale of 0 to 10, with 0 meaning not at all likely and 10 meaning extremely likelydate_rangeTime Frame:Rosacea treatment in the past 4 weeksenhanced_encryptionNoSafety Issue:
- Quality of lifeMeasured using Dermatology Life Quality Index (DLQI): The DLQI consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, and school, personal relationships and treatmentdate_rangeTime Frame:Rosacea treatment in the past 4 weeksenhanced_encryptionNoSafety Issue:
- Treatment satisfactionAssessed by a score on the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q). Scores will be standardized and expressed as a 0-100 standardized scoredate_rangeTime Frame:Rosacea treatment in the past 4 weeksenhanced_encryptionNoSafety Issue:
- Self-reported concerns and importance (a rating scale) of such concerns that patients would consider when switching to a new topical rosacea treatmentExtracted from the Rosacea Treatment Preference Questionnairedate_rangeTime Frame:Rosacea treatment in the past 4 weeks
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A